INSIGHTS AND PERSPECTIVES

SAN ANTONIO — A drug for Type 2 diabetes made by Takeda Pharmaceutical taken in the morning prevented the disease from developing in nearly three-quarters of patients who were at risk, according to a new study in the New England Journal of Medicine.

Researchers enrolled 602 patients through the University of Texas Health Science Center San Antonio and seven other centers and administered Actos (pioglitazone) to them, finding that it prevented Type 2 diabetes in 72% of those whose obesity, ethnicity and other factors put them at risk for the disease.

WHAT IT MEANS AND WHY IT'S IMPORTANT — Almost two-thirds of consumers live within 3 miles of a Walgreens. For the rest of America, Walgreens is using its multichannel strategy to get even closer. The deal with Drugstore.com considerably accelerates the chain's plans.

(THE NEWS: Walgreens boosts online presence with Drugstore.com acquisition. For the full story, click here.)

PALO ALTO, Calif. — Personalization of the in-store customer experience will be a key objective for retailers over the next two years, according to two new Aberdeen Group reports sponsored by HP.

According to the 100 senior retail executives surveyed from such industries as apparel, grocery and department stores, 76% do not possess the technology tools or the business processes for executing Web, catalog or special orders from stores. This challenge is being fueled by rising consumer expectations of rich, multimedia in-store shopping experiences.

PARSIPPANY, N.J. — Four-in-5 menthol smokers would quit if the Food and Drug Administration banned mentholated cigarettes, according to a survey conducted this month with sponsorship from GlaxoSmithKline Consumer Healthcare.

The survey found that smokers of menthol cigarettes — who are disproportionately African-American — feel “twice-addicted” to the menthol and the tobacco, while 74% of them said the menthol made inhalation easier, and 40% said menthol flavoring was the only reason they smoked.

COPENHAGEN — Novo Nordisk said new data showed that its basal insulin analog is just as effective as human basal insulin in Type 1 diabetes patients ages 2 to 5 years.

BETHESDA, Md. — Most patients that suffer from gastroesophageal reflux disease or persistent heartburn symptoms rarely speak with a healthcare provider about their condition, according to a new study conducted on behalf of the American Gastroenterological Association, in partnership with drug maker Takeda.

OAK BROOK, Ill. — Almost all women take on at least one preventive health-and-wellness measure in the morning to start their day, but only half apply lip balm to protect their lips from dryness and sun damage.

In Blistex's grooming routine survey, the lip care brand found that even though 91% of women perform at least one measure that boosts their health and wellness (e.g., taking a vitamin, exercising and applying an anti-aging facial product), their lips often are abandoned, which could put them at risk for infection, Blistex said.

SAN FRANCISCO — Less than 20% of surveyed patients with nasal allergies find their symptoms are completely controlled over a one-week period of treatment, according to a survey performed by drug maker Teva Pharmaceutical Industries.